Proactive Investors - Run By Investors For Investors

Medexus Pharmaceuticals will begin selling Treosulfan in Canada, and will soon look to the US

Medexus Pharmaceuticals Inc (CVE:MDP) (OTC:PDDPF) CEO Ken d’Entremont tells Proactive Investors that Health Canada has authorized the Montreal-based specialty pharma company to distribute Treosulfan through the special access program.

Treosulfana is a conditioning agent used before stem cell transplantation.

The company will look to bring Treosulfann to the US, according to d'Entremont.

View full MDP profile View Profile

Medexus Pharmaceuticals Inc Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use